BioSpace News Archive

Global Genes®, a leading rare disease patient advocacy organization, is proud to announce the 2018 David R. Cox Scholarship recipient, medical student, Kristin Hunt.

RxAnte, Inc., a leading provider of predictive analytics and targeted clinical programs for medication management, announced today the issuance of US Patent No. 10,108,975 for the development of its RxEffect® workflow solution, designed to improve patient medication use on behalf of health plans and care providers.

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, is pleased to announce that the Company has received $14,007,000 from the exercise of warrants of which the expiry date was accelerated to November 14, 2018 (the “Warrants”), as previously announced on October 25, 2018.

Two leading U.S. health systems – Catholic Health Initiatives (CHI) and Dignity Health – who announced a Definitive Agreement to combine their health ministries in December 2017, have chosen “CommonSpirit Health” as the name of their new organization.

AlchemLife TM launched a new line of products in the US this week.

The Society for Clinical Research Sites (SCRS) announced today that GlobalCare Clinical Trials, LLC has joined the organization as a Global Impact Partner (GIP).

The U.S. Food and Drug Administration (FDA) has reported a significant increase in the use of vaping products by youth in the United States.

Tocagen Inc. today announced that Lori Kunkel, M.D. has been named acting chief medical officer, effective November 26, 2018. Asha Das, M.D., senior vice president and chief medical officer will be leaving the company effective November 23, 2018 to allow her to focus on unforeseen and immediate personal matters. The company has initiated a search process to fill the position.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced initial clinical data in patients treated in the Company’s Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant, for the treatment of patients with severe and moderately severe hemophilia B.

Camel-IDS, a Brussels-based company developing cancer-targeted radiopharmaceuticals today announced the completion of a series-A financing round, whereby the company secured funding of EUR 37 million